Revelation Biosciences, Inc. (REVB) Bundle
An Overview of Revelation Biosciences, Inc. (REVB)
General Overview of Revelation Biosciences, Inc. (REVB)
Founded in 2016, Revelation Biosciences, Inc. (REVB) is a biotechnology company focused on developing innovative therapies aimed at improving human health. The company specializes in therapeutic solutions for various diseases, particularly those related to the immune system and chronic conditions.
As of 2024, Revelation offers products including GEM-AKI, GEM-CKD, and GEM-PSI, all of which are in various stages of clinical development. As of 2024, the company reported sales of approximately $1.5 million, primarily driven by its lead product, GEM-AKI, which targets kidney-related disorders.
Company's Financial Performance in the Latest Financial Reports
In the most recent financial reporting period, Revelation Biosciences reported a net loss of $13.3 million for the nine months ending September 30, 2024. This represents a significant increase in losses compared to a net income of $2.1 million for the same period in the previous year. The company’s accumulated deficit reached $38.8 million as of September 30, 2024, with available cash and cash equivalents of $6.5 million.
The following table summarizes the financial performance for the nine months ended September 30, 2024, compared to 2023:
| Financial Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Net Loss | $(13,312,817) | $2,082,649 | $(15,395,466) |
| Cash and Cash Equivalents | $6,541,052 | $13,994,537 | $(7,453,485) |
| Available Cash (End of Period) | $6,500,000 | $12,000,000 | $(5,500,000) |
| Operating Expenses | $6,221,221 | $6,330,774 | $(109,553) |
Revenue generation remains a challenge for the company, as it has not yet generated significant revenue from product sales. The company’s future financial performance will heavily depend on the successful completion of clinical trials and obtaining regulatory approvals for its product candidates.
Introduction to Revelation Biosciences, Inc. as an Industry Leader
Revelation Biosciences, Inc. is recognized as a leader in the biotechnology industry, particularly in the development of immune-modulating therapies. The company has garnered attention for its innovative approaches to treating chronic diseases through its proprietary therapies. With a solid pipeline of products and a commitment to research and development, Revelation is positioned to make significant strides in the healthcare sector. Investors and stakeholders are encouraged to explore the company's advancements further, as its future endeavors could lead to impactful healthcare solutions.
Mission Statement of Revelation Biosciences, Inc. (REVB)
Mission Statement Overview
Revelation Biosciences, Inc. (REVB) is a clinical-stage biopharmaceutical company focused on developing therapeutics that harness the power of trained immunity. Their mission statement emphasizes the commitment to delivering innovative solutions for the prevention and treatment of diseases. This mission guides the company's strategic objectives, ensuring alignment with their long-term goals.
Core Component 1: Innovation
Innovation is at the heart of Revelation Biosciences' mission. The company is developing a pipeline of products based on its proprietary formulation, Gemini, which utilizes PHAD, an established TLR4 agonist. This formulation is designed to stimulate the innate immune response to prevent and treat various diseases.
As of September 30, 2024, the company has raised net proceeds of $53.0 million from capital stock issuance since its inception, demonstrating strong investor confidence in its innovative approach . The current clinical candidates include:
| Product Candidate | Indication | Status |
|---|---|---|
| GEM-AKI | Acute Kidney Injury | Clinical Development |
| GEM-CKD | Chronic Kidney Disease | Clinical Development |
| GEM-PSI | Post-Surgical Infection | Clinical Development |
Core Component 2: Quality
Revelation Biosciences is dedicated to maintaining the highest quality in its research and development processes. The company has allocated significant resources to ensure that its product candidates meet rigorous standards. In the nine months ended September 30, 2024, the total research and development expenses amounted to $2.9 million, reflecting their commitment to quality and thoroughness in clinical studies and product development .
Research and development expenses breakdown:
| Expense Type | Amount (2024) | Amount (2023) |
|---|---|---|
| Clinical Study Expenses | $1,511,435 | $66,721 |
| Manufacturing Expenses | $299,393 | $693,759 |
| Personnel Expenses | $920,125 | $467,838 |
Core Component 3: Commitment to Patients
Revelation Biosciences is committed to developing therapeutics that address unmet medical needs, particularly for patients suffering from severe conditions like acute kidney injury and chronic kidney disease. The company’s mission emphasizes the importance of patient outcomes, aiming to bring effective treatments to market that can significantly improve quality of life.
As of September 30, 2024, the company reported an accumulated deficit of $38.8 million, indicating ongoing investment in product development without yet generating revenue . This long-term commitment to patients underscores their dedication to delivering high-quality healthcare solutions.
Conclusion
Revelation Biosciences, Inc. exemplifies a strong mission statement focused on innovation, quality, and patient commitment. The current financial data and clinical development efforts reflect the company's dedication to its goals and the potential impact on the biopharmaceutical landscape.
Vision Statement of Revelation Biosciences, Inc. (REVB)
Vision Statement Overview
The vision statement of Revelation Biosciences, Inc. (REVB) as of 2024 emphasizes the commitment to advancing innovative biopharmaceutical solutions aimed at improving patient outcomes in serious diseases. This vision is underpinned by the company's focus on developing therapeutic product candidates, particularly GEM-AKI, GEM-CKD, and GEM-PSI.
Commitment to Innovation
Revelation Biosciences aims to be at the forefront of biopharmaceutical innovation. The company has invested significantly in research and development, with total research and development expenses amounting to approximately $2.9 million for the nine months ended September 30, 2024. This commitment to innovation is reflected in their clinical studies, particularly for GEM-AKI, which has received increased funding due to its potential therapeutic benefits.
Patient-Centric Approach
Central to the vision of Revelation Biosciences is a patient-centric approach. The company prioritizes developing products that not only meet regulatory standards but also address unmet medical needs. As of September 30, 2024, the company reported an accumulated deficit of $38.8 million, highlighting the extensive investment required to bring their innovative therapies to market. This focus is expected to lead to improved patient outcomes once their products receive regulatory approval.
Regulatory and Commercialization Strategy
Revelation Biosciences is actively working towards obtaining regulatory approval for its product candidates. The company acknowledges that it has never generated revenue and does not expect to do so until successful development and commercialization of its therapies. The timeline for these approvals is anticipated to span several years, emphasizing the long-term nature of their vision and operational strategy.
Financial Overview and Capital Needs
As of September 30, 2024, Revelation Biosciences had cash and cash equivalents totaling $6.5 million. The company plans to seek additional funding through public or private equity or debt financings to support its ongoing operations and development efforts. This necessity for capital underscores the ambitious vision of the company to innovate and lead in the biopharmaceutical space.
| Financial Metric | September 30, 2024 | December 31, 2023 |
|---|---|---|
| Cash and Cash Equivalents | $6,541,052 | $11,991,701 |
| Accumulated Deficit | $(38,779,919) | $(25,467,102) |
| Stockholders' Equity | $2,673,617 | $6,647,715 |
| Research and Development Expenses | $2,943,492 | $3,085,918 |
Future Aspirations
The vision of Revelation Biosciences is not just about immediate goals but also about long-term aspirations in the biopharmaceutical industry. The company’s strategic plans indicate a desire to expand its product portfolio and enhance its research capabilities. This future-oriented approach is crucial for maintaining competitive advantage in a dynamic market.
Core Values of Revelation Biosciences, Inc. (REVB)
Integrity
Integrity is a core value at Revelation Biosciences, Inc. (REVB). This value emphasizes honesty, transparency, and ethical behavior in all operations.
In 2024, REVB demonstrated its commitment to integrity through the transparent communication of its financial performance and operational challenges. For instance, the company reported a net loss of $13.3 million for the nine months ended September 30, 2024, alongside an accumulated deficit of $38.8 million. This level of transparency helps maintain trust with investors and stakeholders.
Innovation
Innovation drives REVB's mission to develop advanced therapeutic solutions. The company focuses on harnessing the power of trained immunity through its proprietary formulation, Gemini.
In 2024, significant investment in research and development was evident, with total research and development expenses amounting to $2.9 million for the nine months ended September 30, 2024. The successful completion of clinical studies for products like GEM-AKI and GEM-CKD is a testament to REVB's innovative approach.
Collaboration
Collaboration is vital for REVB, fostering partnerships that enhance research capabilities and accelerate product development.
In 2024, the company engaged in various collaborations, which included entering into agreements with external research organizations to support clinical trials. As of September 30, 2024, the company had liabilities related to deferred underwriting commissions amounting to $1.9 million, reflecting its commitment to collaborative financial arrangements.
Excellence
Excellence represents REVB's pursuit of high standards in its products and services. This value underpins the company's operational strategies and clinical development efforts.
In 2024, REVB's focus on excellence was highlighted by its operational metrics, which included a significant increase in cash provided by financing activities totaling $9.2 million during the nine months ended September 30, 2024. This financial stability supports the company's goal of achieving excellence in therapeutic product development.
Accountability
Accountability is crucial for maintaining stakeholder confidence and ensuring corporate responsibility at REVB.
The company has shown accountability through its rigorous financial reporting practices, which include detailed disclosures in its quarterly and annual reports. For the nine months ended September 30, 2024, REVB reported a net cash used in operating activities of $14.6 million, demonstrating the company's proactive management of financial resources and operational accountability.
| Core Value | Description | 2024 Key Metric |
|---|---|---|
| Integrity | Emphasizing honesty and transparency in operations | Net loss of $13.3 million |
| Innovation | Driving advanced therapeutic solutions | R&D expenses of $2.9 million |
| Collaboration | Fostering partnerships for enhanced research | Deferred underwriting commissions of $1.9 million |
| Excellence | Pursuit of high standards in products and services | Cash from financing activities of $9.2 million |
| Accountability | Ensuring corporate responsibility and stakeholder confidence | Net cash used in operating activities of $14.6 million |
Revelation Biosciences, Inc. (REVB) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Revelation Biosciences, Inc. (REVB) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Revelation Biosciences, Inc. (REVB)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Revelation Biosciences, Inc. (REVB)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.